NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX). Shareholders who purchased shares of NUTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/nutex-health-inc-loss-submission-form/?id=166132&from=3 CLASS PERIOD: August 8, ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PubMatic, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions that affected the company's stock value during a specified period [1][3]. Summary by Relevant Sections Class Action Details - The class period for the lawsuit is from February 27, 2025, to August 11, 2025 [3]. - Allegations include that PubMatic failed to disclose a significant shift of clients from a top demand side platform buyer to a new platform, leading to reduced ad spend and revenue [3]. Shareholder Actions - Shareholders are encouraged to register for the class action by October 20, 2025, to potentially be appointed as lead plaintiffs [4]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during a specified class period [1][3]. Group 1: Allegations - The complaint alleges that LifeMD's management materially overstated the company's competitive position [3]. - It is claimed that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [3]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as May 7, 2025, to August 5, 2025 [3]. - Shareholders are encouraged to register for the class action by the deadline of October 25, 2025, to potentially be appointed as lead plaintiffs [4]. - Participation in the case does not incur any cost or obligation for the shareholders [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm is committed to ensuring companies adhere to responsible business practices and engage in good corporate citizenship [5]. - The firm seeks recovery for investors who experienced losses due to false or misleading statements that led to artificial inflation of the company's stock [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Sable Offshore Corp. regarding a class action lawsuit due to alleged misleading statements made by the company during a specific period [1][4]. Class Period - The class period for the lawsuit is defined as from May 19, 2025, to June 3, 2025, which includes transactions related to the company's secondary public offering on May 21, 2025 [3]. Allegations - The complaint alleges that Sable Offshore Corp. falsely claimed to have restarted oil production off the coast of California, which was not the case. This misrepresentation led to materially false and misleading statements about the company's business and operations [4]. Deadline and Next Steps - Shareholders are encouraged to register for the class action by September 26, 2025, to participate in potential recovery. Registration will also provide access to portfolio monitoring software for status updates on the case [5]. Law Firm's Commitment - The Gross Law Firm emphasizes its mission to protect investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices that inflate stock prices [6].

Core Viewpoint - Neogen Corporation (NASDAQ: NEOG) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its integration with the Food Safety Division of 3M Company, which misled investors about the progress of the integration [3]. Group 1 - The class period for the lawsuit is from January 5, 2023, to June 3, 2025 [3]. - Allegations include that the company downplayed inefficiencies arising from the integration and assured investors of their commitment to resolving these issues quickly [3]. - Shareholders are encouraged to register for the class action by September 16, 2025, to potentially become lead plaintiffs [4]. Group 2 - The Gross Law Firm is representing the shareholders and is recognized for protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, leading to a significant drop in stock price after the withdrawal of its 2025 guidance [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Centene's management made overly positive statements while concealing adverse facts about the company's performance [1]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [1]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% [1]. Group 2: Class Action Details - Shareholders who purchased shares during the class period from December 12, 2024, to June 30, 2025, are encouraged to register for the class action, with a deadline of September 8, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [3].

Core Points - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit due to alleged misleading statements and undisclosed issues affecting the company's performance [1][2] - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, during which the company reportedly faced "adoption challenges" and structural issues leading to declines in sales and utilization [1] - Allegations include overstated demand for RxSight's products and the likelihood of the company failing to meet its financial guidance for fiscal year 2025 [1] Company and Industry Summary - The lawsuit claims that the defendants made materially false and misleading statements about RxSight's business operations and prospects, which misled investors [1] - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially become lead plaintiffs and participate in recovery efforts [2] - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring companies adhere to responsible business practices [3]

Core Viewpoint - Unicycive Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [2][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 29, 2024, to June 27, 2025 [2]. - Allegations include overstating Unicycive's readiness to meet FDA manufacturing compliance and the regulatory prospects of its oxylanthanum carbonate new drug application [2]. Group 2: Shareholder Actions - Shareholders who purchased UNCY shares during the class period are encouraged to register for the class action and can seek lead plaintiff status by the deadline of October 14, 2025 [3]. - Registration allows shareholders to receive updates through portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [4].

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its growth and the impact of its CEO's health on the company's performance, leading to a significant drop in stock price following disappointing financial results [1][2]. Summary by Sections Allegations - The complaint claims that C3.ai's management provided overly positive statements while concealing material adverse facts about the company's growth, particularly the CEO's health affecting deal closures and overall performance [1]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health [1]. Stock Price Impact - Following the announcement on August 8, 2025, C3.ai's stock price fell from $22.13 per share to $16.47 per share by August 11, 2025, marking a decline of approximately 25.58% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from February 26, 2025, to August 8, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for October 21, 2025 [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, seeking recovery for losses incurred due to misleading statements by companies [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sable Offshore Corp. regarding a class action lawsuit due to alleged misleading statements made by the company during a specific period [1][4]. Group 1: Class Action Details - The class period for the lawsuit is from May 19, 2025, to June 3, 2025, including transactions related to the company's secondary public offering on May 21, 2025 [3]. - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [5]. Group 2: Allegations Against Sable Offshore Corp. - The complaint alleges that Sable Offshore Corp. falsely claimed to have restarted oil production off the coast of California when it had not, leading to materially false and misleading statements about the company's business and operations [4]. - The lawsuit claims that investors suffered damages when the true details about the company's operations were revealed [4]. Group 3: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case [5]. - The deadline for seeking lead plaintiff status is September 26, 2025 [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [6].